Seeking Alpha

Janssen takes steps towards Doxil manufacturing transition

  • Janssen Pharmaceuticals (JNJ -0.7%) says it has "reached an initial agreement to lease some parts" of a Bedford, Ohio Ben Venue plant, a move which shows "steps are being taken to transition manufacturing" of Doxil, the popular cancer drug that has been in short supply since 2011 when Ben Venue halted production amid manufacturing problems.
  • Previously, the plan was to close the plant by the end of the year.
  • "There are multiple steps required to transition manufacturing and any plans are subject to health authority approvals," a JNJ spokesperson remarked.
  • For more, see: Doxil may remain scarce amid JNJ, Boehringer dispute
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: